These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 30604512)

  • 1. Monoamine oxidase-B inhibitors as potential neurotherapeutic agents: An overview and update.
    Tripathi RKP; Ayyannan SR
    Med Res Rev; 2019 Sep; 39(5):1603-1706. PubMed ID: 30604512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Privileged scaffolds as MAO inhibitors: Retrospect and prospects.
    Tripathi AC; Upadhyay S; Paliwal S; Saraf SK
    Eur J Med Chem; 2018 Feb; 145():445-497. PubMed ID: 29335210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities.
    Kumar B; Gupta VP; Kumar V
    Curr Drug Targets; 2017; 18(1):87-97. PubMed ID: 26648064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comprehensive review of monoamine oxidase inhibitors as Anti-Alzheimer's disease agents: A review.
    Manzoor S; Hoda N
    Eur J Med Chem; 2020 Nov; 206():112787. PubMed ID: 32942081
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Comprehensive Review of Monoamine Oxidase-A Inhibitors in their Syntheses and Potencies.
    Rehuman NA; Mathew B; Jat RK; Nicolotti O; Kim H
    Comb Chem High Throughput Screen; 2020; 23(9):898-914. PubMed ID: 32342809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Machine learning driven web-based app platform for the discovery of monoamine oxidase B inhibitors.
    Kumar S; Bhowmik R; Oh JM; Abdelgawad MA; Ghoneim MM; Al-Serwi RH; Kim H; Mathew B
    Sci Rep; 2024 Feb; 14(1):4868. PubMed ID: 38418571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.
    Youdim MBH
    J Neural Transm (Vienna); 2018 Nov; 125(11):1719-1733. PubMed ID: 30341696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression.
    Naoi M; Riederer P; Maruyama W
    J Neural Transm (Vienna); 2016 Feb; 123(2):91-106. PubMed ID: 25604428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
    Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
    Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drugs related to monoamine oxidase activity.
    Fišar Z
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():112-24. PubMed ID: 26944656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival.
    Naoi M; Maruyama W; Inaba-Hasegawa K
    Curr Top Med Chem; 2012; 12(20):2177-88. PubMed ID: 23231395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel monoamine oxidase inhibitors based on the privileged 2-imidazoline molecular framework.
    Shetnev A; Osipyan A; Baykov S; Sapegin A; Chirkova Z; Korsakov M; Petzer A; Engelbrecht I; Petzer JP
    Bioorg Med Chem Lett; 2019 Jan; 29(1):40-46. PubMed ID: 30455149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases.
    Youdim MB; Fridkin M; Zheng H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1455-71. PubMed ID: 15480846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAO inhibitors and their wider applications: a patent review.
    Carradori S; Secci D; Petzer JP
    Expert Opin Ther Pat; 2018 Mar; 28(3):211-226. PubMed ID: 29324067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoamine Oxidase Inhibitors: From Classic to New Clinical Approaches.
    Duarte P; Cuadrado A; León R
    Handb Exp Pharmacol; 2021; 264():229-259. PubMed ID: 32852645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sembragiline: A Novel, Selective Monoamine Oxidase Type B Inhibitor for the Treatment of Alzheimer's Disease.
    Borroni E; Bohrmann B; Grueninger F; Prinssen E; Nave S; Loetscher H; Chinta SJ; Rajagopalan S; Rane A; Siddiqui A; Ellenbroek B; Messer J; Pähler A; Andersen JK; Wyler R; Cesura AM
    J Pharmacol Exp Ther; 2017 Sep; 362(3):413-423. PubMed ID: 28642233
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular aspects of monoamine oxidase B.
    Ramsay RR
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():81-9. PubMed ID: 26891670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Understanding the Molecular Determinant of Reversible Human Monoamine Oxidase B Inhibitors Containing 2H-Chromen-2-One Core: Structure-Based and Ligand-Based Derived Three-Dimensional Quantitative Structure-Activity Relationships Predictive Models.
    Mladenović M; Patsilinakos A; Pirolli A; Sabatino M; Ragno R
    J Chem Inf Model; 2017 Apr; 57(4):787-814. PubMed ID: 28291352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elucidating the mechanism of action and potential interactions of MAO-B inhibitors.
    Bainbridge JL; Page RL; Ruscin JM
    Neurol Clin; 2008 Aug; 26(3 Suppl):S85-96, vi. PubMed ID: 18774444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monoamine oxidase B inhibitors based on natural privileged scaffolds: A review of systematically structural modification.
    Lv Y; Zheng Z; Liu R; Guo J; Zhang C; Xie Y
    Int J Biol Macromol; 2023 Nov; 251():126158. PubMed ID: 37549764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.